BV-2 microglial cell line was developed by immortalizing primary mouse microglial cells with v-raf/v-myc recombinant retrovirus, in the laboratory of Dr Blasi [36 (
link)] and was a generous gift from Dr Alba Minelli (University of Perugia, Perugia, Italy). Cells were maintained in
RPMI 1640 medium (GE Healthcare Life Sciences, Freiburg, Germany) supplemented with 10% heat-inactivated fetal bovine serum (
FBS, PAA Laboratories GmbH, Pasching, Austria) and 1%
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) at 37°C in a humidified incubator under a 95% air/5% CO
2. When cells reached approximately 80% confluence, they were detached with 0.1%
trypsin-EDTA (PAA Laboratories GmbH, Pasching, Austria), seeded into appropriate dishes and incubated overnight. Then BV-2 cells were pre-treated for 30 min with different concentrations of
benfotiamine (Sigma-Aldrich, Munich, Germany; 50, 100 or 250 μM) before stimulation with LPS from
Escherichia coli serotype 026:B6 (Sigma-Aldrich, Munich, Germany; 1μg/ml). Incubation time with LPS varied depending on the purpose of the experiment.
Bozic I., Savic D., Laketa D., Bjelobaba I., Milenkovic I., Pekovic S., Nedeljkovic N, & Lavrnja I. (2015). Benfotiamine Attenuates Inflammatory Response in LPS Stimulated BV-2 Microglia. PLoS ONE, 10(2), e0118372.